The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...
This study suggests that the PDT plus ranibizumab injection is far superior to PDT alone. However, the main question that this study cannot answer is whether PDT plus ranibizumab injection is ...
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback